Professor | Jun Tian | Asia Growth Partners

Upload Avatar (500 x 500)

Name

Jun Tian

Contact Information

tianj@sustech.edu.cn

Language ability

English, Chinese

Province

Guangdong

University/Lab Affiliation and Title	Southern University of Science and Technology
Faculty	Medical School
Academic Background & Achievements	2009-2013 Bachelor: Nankai University 2013-2018 PhD: McGill University, Canada Received Outstanding PhD Graduate Award from McGill University
Work Experience	2023.08-present Southern University of Science and Technology, Medical School, Assistant Professor 2019-2023 Harvard Medical School, Massachusetts General Hospital, Postdoctoral Researcher 2018-2019 McGill University Health Centre, Postdoctoral Researcher
Awards	2018: Outstanding PhD Graduate Award, McGill University 2017: Excellent Productivity Award, McGill University Medical School

University/Lab Affiliation and Title

Southern University of Science and Technology

Faculty

Medical School

Academic Background & Achievements

Work Experience

2023.08-present Southern University of Science and Technology, Medical School, Assistant Professor
2019-2023 Harvard Medical School, Massachusetts General Hospital, Postdoctoral Researcher
2018-2019 McGill University Health Centre, Postdoctoral Researcher

Awards

Areas of Focus	Cancer targeted and immunotherapy Drug resistance mechanisms Development of tumor organoid models and drug testing
Publications	Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial, Jun Tian et al., 2023 Targeting TBK1 to overcome resistance to cancer immunotherapy, Jun Tian et al., 2023 Identification of MFGE8 and KLK5/7 as mediators of breast tumorigenesis and resistance to COX-2 inhibition, Jun Tian et al., 2021 Prolactin receptor-driven combined luminal and epithelial differentiation in breast cancer restricts plasticity, stemness, tumorigenesis and metastasis, Jun Tian et al., 2021 Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells, Jun Tian et al., 2018 KiSS1 gene as a novel mediator of TGFβ-mediated cell invasion in triple negative breast cancer, Jun Tian et al., 2018 Cyclooxygenase-2 regulates TGFβ-induced cancer stemness in triple-negative breast cancer, Jun Tian et al., 2017 Critical Role of Myeloid-Derived Suppressor Cells in Tumor-Induced Liver Immune Suppression through Inhibition of NKT Cell Function, Jun Tian et al., 2017 The leukemia inhibitory factor (LIF) and p21 mediate the TGFβ tumor suppressive effects in human cutaneous melanoma, Jun Tian et al., 2015 Breast cancer anti-estrogen resistance 3 inhibits transforming growth factor β/Smad signaling and associates with favorable breast cancer disease outcomes, Jun Tian et al., 2014

Areas of Focus

Cancer targeted and immunotherapy
Drug resistance mechanisms
Development of tumor organoid models and drug testing

Publications

Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial, Jun Tian et al., 2023
Targeting TBK1 to overcome resistance to cancer immunotherapy, Jun Tian et al., 2023
Identification of MFGE8 and KLK5/7 as mediators of breast tumorigenesis and resistance to COX-2 inhibition, Jun Tian et al., 2021
Prolactin receptor-driven combined luminal and epithelial differentiation in breast cancer restricts plasticity, stemness, tumorigenesis and metastasis, Jun Tian et al., 2021
Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells, Jun Tian et al., 2018
KiSS1 gene as a novel mediator of TGFβ-mediated cell invasion in triple negative breast cancer, Jun Tian et al., 2018
Cyclooxygenase-2 regulates TGFβ-induced cancer stemness in triple-negative breast cancer, Jun Tian et al., 2017
Critical Role of Myeloid-Derived Suppressor Cells in Tumor-Induced Liver Immune Suppression through Inhibition of NKT Cell Function, Jun Tian et al., 2017
The leukemia inhibitory factor (LIF) and p21 mediate the TGFβ tumor suppressive effects in human cutaneous melanoma, Jun Tian et al., 2015
Breast cancer anti-estrogen resistance 3 inhibits transforming growth factor β/Smad signaling and associates with favorable breast cancer disease outcomes, Jun Tian et al., 2014

Cancer Targeted Therapy Immunotherapy Drug Resistance Mechanisms Tumor Organoid Models Drug Testing Oncology Therapeutic Strategies

Hao Chen - Southern University of Science and Technology

Jun Che - Southern University of Science and Technology

Peng Tan - Southern University of Science and Technology

View All

Personal Information